Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Low high-density lipoprotein cholesterol to monitor long-term average increased triglycerides.

Langsted A, Jensen AMR, Varbo A, Nordestgaard BG.

J Clin Endocrinol Metab. 2019 Dec 11. pii: dgz265. doi: 10.1210/clinem/dgz265. [Epub ahead of print]

PMID:
31822888
2.

Lp(a) (Lipoprotein[a])-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study.

Madsen CM, Kamstrup PR, Langsted A, Varbo A, Nordestgaard BG.

Arterioscler Thromb Vasc Biol. 2019 Oct 3:ATVBAHA119312951. doi: 10.1161/ATVBAHA.119.312951. [Epub ahead of print]

PMID:
31578080
3.

Response to 'Lipoprotein(a): it is not the cholesterol content: it is the apolipoprotein(a)!'

Langsted A, Kamstrup PR, Nordestgaard BG.

Eur Heart J. 2019 Nov 14;40(43):3577. doi: 10.1093/eurheartj/ehz607. No abstract available.

PMID:
31535133
4.

Lipoprotein(a) Should Be Measured in All Individuals Suspected of Having Familial Hypercholesterolemia.

Langsted A, Nordestgaard BG.

Clin Chem. 2019 Oct;65(10):1190-1192. doi: 10.1373/clinchem.2019.308650. Epub 2019 Aug 6. No abstract available.

PMID:
31387887
5.

Elevated Lipoprotein(a) and Risk of Ischemic Stroke.

Langsted A, Nordestgaard BG, Kamstrup PR.

J Am Coll Cardiol. 2019 Jul 9;74(1):54-66. doi: 10.1016/j.jacc.2019.03.524.

PMID:
31272552
6.

Reply to: "Seasonal variations of lipid profiles in a French cohort".

Langsted A, Vedel-Krogh S, Kobylecki CJ, Nordestgaard BG.

Atherosclerosis. 2019 Jul;286:184-186. doi: 10.1016/j.atherosclerosis.2019.05.015. Epub 2019 May 24. No abstract available.

PMID:
31151744
7.

Antisense Oligonucleotides Targeting Lipoprotein(a).

Langsted A, Nordestgaard BG.

Curr Atheroscler Rep. 2019 May 20;21(8):30. doi: 10.1007/s11883-019-0792-8. Review.

PMID:
31111240
8.

A third of nonfasting plasma cholesterol is in remnant lipoproteins: Lipoprotein subclass profiling in 9293 individuals.

Balling M, Langsted A, Afzal S, Varbo A, Davey Smith G, Nordestgaard BG.

Atherosclerosis. 2019 Jul;286:97-104. doi: 10.1016/j.atherosclerosis.2019.05.011. Epub 2019 May 9.

PMID:
31108411
9.

The Christmas holidays are immediately followed by a period of hypercholesterolemia.

Vedel-Krogh S, Kobylecki CJ, Nordestgaard BG, Langsted A.

Atherosclerosis. 2019 Feb;281:121-127. doi: 10.1016/j.atherosclerosis.2018.12.011. Epub 2018 Dec 19.

PMID:
30658187
10.

High lipoprotein(a) and high risk of mortality.

Langsted A, Kamstrup PR, Nordestgaard BG.

Eur Heart J. 2019 Sep 1;40(33):2760-2770. doi: 10.1093/eurheartj/ehy902.

PMID:
30608559
11.

Smoking is Associated with Increased Risk of Major Bleeding: A Prospective Cohort Study.

Langsted A, Nordestgaard BG.

Thromb Haemost. 2019 Jan;119(1):39-47. doi: 10.1055/s-0038-1675798. Epub 2018 Dec 31.

PMID:
30597498
12.

Nonfasting versus fasting lipid profile for cardiovascular risk prediction.

Langsted A, Nordestgaard BG.

Pathology. 2019 Feb;51(2):131-141. doi: 10.1016/j.pathol.2018.09.062. Epub 2018 Dec 3. Review.

PMID:
30522787
13.

Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting.

Verbeek R, Hoogeveen RM, Langsted A, Stiekema LCA, Verweij SL, Hovingh GK, Wareham NJ, Khaw KT, Boekholdt SM, Nordestgaard BG, Stroes ESG.

Eur Heart J. 2018 Jul 14;39(27):2589-2596. doi: 10.1093/eurheartj/ehy334.

14.

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis.

Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybjærg-Hansen A, Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C, Trompet S, Jukema JW, Sattar N, Di Angelantonio E, Saleheen D, Howson JMM, Nordestgaard BG, Butterworth AS, Danesh J; European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium.

JAMA Cardiol. 2018 Jul 1;3(7):619-627. doi: 10.1001/jamacardio.2018.1470.

15.

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.

Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, Watts GF, Borén J, Baum H, Bruckert E, Catapano A, Descamps OS, von Eckardstein A, Kamstrup PR, Kolovou G, Kronenberg F, Langsted A, Pulkki K, Rifai N, Sypniewska G, Wiklund O, Nordestgaard BG; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative.

Clin Chem. 2018 Jul;64(7):1006-1033. doi: 10.1373/clinchem.2018.287037. Epub 2018 May 14.

16.

Advances in lipid-lowering therapy through gene-silencing technologies.

Nordestgaard BG, Nicholls SJ, Langsted A, Ray KK, Tybjærg-Hansen A.

Nat Rev Cardiol. 2018 May;15(5):261-272. doi: 10.1038/nrcardio.2018.3. Epub 2018 Feb 8. Review.

PMID:
29417937
17.

Chylomicronemia risk factors ranked by importance for the individual and community in 108 711 women and men.

Pedersen SB, Varbo A, Langsted A, Nordestgaard BG.

J Intern Med. 2018 Apr;283(4):392-404. doi: 10.1111/joim.12713. Epub 2017 Dec 4.

PMID:
29130593
18.

Exome-wide association study of plasma lipids in >300,000 individuals.

Liu DJ, Peloso GM, Yu H, Butterworth AS, Wang X, Mahajan A, Saleheen D, Emdin C, Alam D, Alves AC, Amouyel P, Di Angelantonio E, Arveiler D, Assimes TL, Auer PL, Baber U, Ballantyne CM, Bang LE, Benn M, Bis JC, Boehnke M, Boerwinkle E, Bork-Jensen J, Bottinger EP, Brandslund I, Brown M, Busonero F, Caulfield MJ, Chambers JC, Chasman DI, Chen YE, Chen YI, Chowdhury R, Christensen C, Chu AY, Connell JM, Cucca F, Cupples LA, Damrauer SM, Davies G, Deary IJ, Dedoussis G, Denny JC, Dominiczak A, Dubé MP, Ebeling T, Eiriksdottir G, Esko T, Farmaki AE, Feitosa MF, Ferrario M, Ferrieres J, Ford I, Fornage M, Franks PW, Frayling TM, Frikke-Schmidt R, Fritsche LG, Frossard P, Fuster V, Ganesh SK, Gao W, Garcia ME, Gieger C, Giulianini F, Goodarzi MO, Grallert H, Grarup N, Groop L, Grove ML, Gudnason V, Hansen T, Harris TB, Hayward C, Hirschhorn JN, Holmen OL, Huffman J, Huo Y, Hveem K, Jabeen S, Jackson AU, Jakobsdottir J, Jarvelin MR, Jensen GB, Jørgensen ME, Jukema JW, Justesen JM, Kamstrup PR, Kanoni S, Karpe F, Kee F, Khera AV, Klarin D, Koistinen HA, Kooner JS, Kooperberg C, Kuulasmaa K, Kuusisto J, Laakso M, Lakka T, Langenberg C, Langsted A, Launer LJ, Lauritzen T, Liewald DCM, Lin LA, Linneberg A, Loos RJF, Lu Y, Lu X, Mägi R, Malarstig A, Manichaikul A, Manning AK, Mäntyselkä P, Marouli E, Masca NGD, Maschio A, Meigs JB, Melander O, Metspalu A, Morris AP, Morrison AC, Mulas A, Müller-Nurasyid M, Munroe PB, Neville MJ, Nielsen JB, Nielsen SF, Nordestgaard BG, Ordovas JM, Mehran R, O'Donnell CJ, Orho-Melander M, Molony CM, Muntendam P, Padmanabhan S, Palmer CNA, Pasko D, Patel AP, Pedersen O, Perola M, Peters A, Pisinger C, Pistis G, Polasek O, Poulter N, Psaty BM, Rader DJ, Rasheed A, Rauramaa R, Reilly DF, Reiner AP, Renström F, Rich SS, Ridker PM, Rioux JD, Robertson NR, Roden DM, Rotter JI, Rudan I, Salomaa V, Samani NJ, Sanna S, Sattar N, Schmidt EM, Scott RA, Sever P, Sevilla RS, Shaffer CM, Sim X, Sivapalaratnam S, Small KS, Smith AV, Smith BH, Somayajula S, Southam L, Spector TD, Speliotes EK, Starr JM, Stirrups KE, Stitziel N, Strauch K, Stringham HM, Surendran P, Tada H, Tall AR, Tang H, Tardif JC, Taylor KD, Trompet S, Tsao PS, Tuomilehto J, Tybjaerg-Hansen A, van Zuydam NR, Varbo A, Varga TV, Virtamo J, Waldenberger M, Wang N, Wareham NJ, Warren HR, Weeke PE, Weinstock J, Wessel J, Wilson JG, Wilson PWF, Xu M, Yaghootkar H, Young R, Zeggini E, Zhang H, Zheng NS, Zhang W, Zhang Y, Zhou W, Zhou Y, Zoledziewska M; Charge Diabetes Working Group; EPIC-InterAct Consortium; EPIC-CVD Consortium; GOLD Consortium; VA Million Veteran Program, Howson JMM, Danesh J, McCarthy MI, Cowan CA, Abecasis G, Deloukas P, Musunuru K, Willer CJ, Kathiresan S.

Nat Genet. 2017 Dec;49(12):1758-1766. doi: 10.1038/ng.3977. Epub 2017 Oct 30.

19.

High Lipoprotein(a) and Low Risk of Major Bleeding in Brain and Airways in the General Population: a Mendelian Randomization Study.

Langsted A, Kamstrup PR, Nordestgaard BG.

Clin Chem. 2017 Nov;63(11):1714-1723. doi: 10.1373/clinchem.2017.276931. Epub 2017 Sep 6.

20.

Reply to: "Appropriate use of cholesterol-lowering therapy".

Langsted A, Freiberg JJ, Nordestgaard BG.

Atherosclerosis. 2017 Jul;262:200-201. doi: 10.1016/j.atherosclerosis.2017.03.017. Epub 2017 Mar 10. No abstract available.

PMID:
28522146
21.

Hypertriglyceridemia and Pancreatitis-New Evidence That Less Is More-Reply.

Pedersen SB, Langsted A, Nordestgaard BG.

JAMA Intern Med. 2017 May 1;177(5):745-746. doi: 10.1001/jamainternmed.2017.0616. No abstract available.

PMID:
28460108
22.

Remnant Cholesterol Elicits Arterial Wall Inflammation and a Multilevel Cellular Immune Response in Humans.

Bernelot Moens SJ, Verweij SL, Schnitzler JG, Stiekema LCA, Bos M, Langsted A, Kuijk C, Bekkering S, Voermans C, Verberne HJ, Nordestgaard BG, Stroes ESG, Kroon J.

Arterioscler Thromb Vasc Biol. 2017 May;37(5):969-975. doi: 10.1161/ATVBAHA.116.308834. Epub 2017 Mar 23.

PMID:
28336558
23.

Extent of undertreatment and overtreatment with cholesterol-lowering therapy according to European guidelines in 92,348 Danes without ischemic cardiovascular disease and diabetes in 2004-2014.

Langsted A, Freiberg JJ, Nordestgaard BG.

Atherosclerosis. 2017 Feb;257:9-15. doi: 10.1016/j.atherosclerosis.2016.11.025. Epub 2016 Nov 24.

PMID:
28038381
24.

Nonfasting Mild-to-Moderate Hypertriglyceridemia and Risk of Acute Pancreatitis.

Pedersen SB, Langsted A, Nordestgaard BG.

JAMA Intern Med. 2016 Dec 1;176(12):1834-1842. doi: 10.1001/jamainternmed.2016.6875.

PMID:
27820614
25.

Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology.

Nordestgaard BG, Langsted A.

J Lipid Res. 2016 Nov;57(11):1953-1975. Epub 2016 Sep 27. Review.

26.

Commentary: Nonfasting remnant cholesterol simplifies triglyceride-rich lipoproteins for clinical use, and metabolomic phenotyping ignites scientific curiosity.

Varbo A, Langsted A, Nordestgaard BG.

Int J Epidemiol. 2016 Oct;45(5):1379-1385. Epub 2016 Aug 30. No abstract available.

PMID:
27581802
27.

Lipoprotein(a) and familial hypercholesterolaemia - Authors' reply.

Langsted A, Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG.

Lancet Diabetes Endocrinol. 2016 Sep;4(9):730-731. doi: 10.1016/S2213-8587(16)30147-4. Epub 2016 Jul 23. No abstract available.

PMID:
27460308
28.

Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cutpoints-A Joint Consensus Statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.

Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Borén J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative.

Clin Chem. 2016 Jul;62(7):930-46. doi: 10.1373/clinchem.2016.258897. Epub 2016 May 27.

29.

PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis.

Langsted A, Nordestgaard BG, Benn M, Tybjærg-Hansen A, Kamstrup PR.

J Clin Endocrinol Metab. 2016 Sep;101(9):3281-7. doi: 10.1210/jc.2016-1206. Epub 2016 May 24.

PMID:
27218270
30.

High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study.

Langsted A, Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG.

Lancet Diabetes Endocrinol. 2016 Jul;4(7):577-87. doi: 10.1016/S2213-8587(16)30042-0. Epub 2016 May 13.

PMID:
27185354
31.

Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine.

Nordestgaard BG, Langsted A, Mora S, Kolovou G, Baum H, Bruckert E, Watts GF, Sypniewska G, Wiklund O, Borén J, Chapman MJ, Cobbaert C, Descamps OS, von Eckardstein A, Kamstrup PR, Pulkki K, Kronenberg F, Remaley AT, Rifai N, Ros E, Langlois M; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) joint consensus initiative.

Eur Heart J. 2016 Jul 1;37(25):1944-58. doi: 10.1093/eurheartj/ehw152. Epub 2016 Apr 26.

32.

Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease.

Jepsen AM, Langsted A, Varbo A, Bang LE, Kamstrup PR, Nordestgaard BG.

Clin Chem. 2016 Apr;62(4):593-604. doi: 10.1373/clinchem.2015.253757. Epub 2016 Feb 17.

33.

How Does Elevated Lipoprotein(a) Cause Aortic Valve Stenosis?

Nordestgaard BG, Langsted A.

J Am Coll Cardiol. 2015 Sep 15;66(11):1247-1249. doi: 10.1016/j.jacc.2015.07.045. No abstract available.

34.

Nonfasting Lipid Profiles: The Way of the Future.

Langsted A, Nordestgaard BG.

Clin Chem. 2015 Sep;61(9):1123-5. doi: 10.1373/clinchem.2015.243139. Epub 2015 Jul 23. No abstract available.

35.

Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100,578 Individuals from the General Population.

Langsted A, Varbo A, Kamstrup PR, Nordestgaard BG.

J Clin Endocrinol Metab. 2015 Jul;100(7):2690-9. doi: 10.1210/jc.2015-1096. Epub 2015 May 4.

PMID:
25938632
36.

Lipoprotein(a): fasting and nonfasting levels, inflammation, and cardiovascular risk.

Langsted A, Kamstrup PR, Nordestgaard BG.

Atherosclerosis. 2014 May;234(1):95-101. doi: 10.1016/j.atherosclerosis.2014.01.049. Epub 2014 Feb 12.

PMID:
24632508
37.

Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up.

Langsted A, Freiberg JJ, Tybjaerg-Hansen A, Schnohr P, Jensen GB, Nordestgaard BG.

J Intern Med. 2011 Jul;270(1):65-75. doi: 10.1111/j.1365-2796.2010.02333.x. Epub 2010 Dec 27.

38.

Nonfasting lipids, lipoproteins, and apolipoproteins in individuals with and without diabetes: 58 434 individuals from the Copenhagen General Population Study.

Langsted A, Nordestgaard BG.

Clin Chem. 2011 Mar;57(3):482-9. doi: 10.1373/clinchem.2010.157164. Epub 2010 Dec 28.

39.

[Fasting and nonfasting lipids--secondary publication].

Langsted A, Freiberg JJ, Nordestgaard BG.

Ugeskr Laeger. 2009 Jun 22;171(26):2184-7. Danish.

PMID:
19678434
40.

Nonfasting hyperlipidemia and cardiovascular disease.

Nordestgaard BG, Langsted A, Freiberg JJ.

Curr Drug Targets. 2009 Apr;10(4):328-35. Review.

PMID:
19355857
41.

Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction.

Langsted A, Freiberg JJ, Nordestgaard BG.

Circulation. 2008 Nov 11;118(20):2047-56. doi: 10.1161/CIRCULATIONAHA.108.804146. Epub 2008 Oct 27.

PMID:
18955664

Supplemental Content

Loading ...
Support Center